GW
XLRN

GW & Wade’s Acceleron Pharma XLRN Stock Holding History

GW & Wade’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-10,157
Closed -$268K – 247
2016
Q1 		$268K Hold
10,157
– – 0.05% 178
2015
Q4 		$495K Sell
10,157
-1,843
-15% -$66.3K 0.1% 119
2015
Q3 		$299K Hold
12,000
– – 0.07% 163
2015
Q2 		$380K Hold
12,000
– – 0.08% 164
2015
Q1 		$457K Buy
+12,000
New +$477K 0.09% 145

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PVMCI
Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

GW & Wade's XLRN Position: Q2 2016 in Review

GW & Wade sold out of Acceleron Pharma (XLRN) in Q2 2016, closing a stake of 10,157 shares — an estimated $268K sold.

GW & Wade first reported a position in XLRN in Q1 2015 and held it in 5 quarters. The position peaked at $495K in Q4 2015. 136 funds tracked by Wall St. Rank hold XLRN as of Q2 2016.

  • GW & Wade reported no remaining Acceleron Pharma position as of Q2 2016 after selling out during the quarter.
  • GW & Wade sold 10,157 Acceleron Pharma shares in Q2 2016, an estimated $268K.
  • GW & Wade first reported a position in Acceleron Pharma in Q1 2015 and held it in 5 quarters.
  • GW & Wade's Acceleron Pharma position peaked at $495K in Q4 2015.
  • 136 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2016.

Based on GW & Wade's 13F filing for Q2 2016, filed 5 Aug 2016.